RxDoctor Payments Data

Hailey Pomonis

Psychiatric/Mental Health · Bismarck, NDNPI 1750980124

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 24.4% of the total. Reporting peaked in 2024 at $219 and has fallen 74.4% since, to $56 in 2025.

$295in general payments, 2019–2025

Across 12 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$72
  • AbbVie$66
  • Sage Therapeutics, LLC$34
  • Lundbeck LLC$26
  • Neurocrine Biosciences, Inc.$23
  • E.r. Squibb & Sons, L.L.C.$20
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$295 in reported general payments places this provider in the 55th percentile of 92 psychiatric/mental health providers in North Dakota.

See all psychiatric/mental health providers in North Dakota

Medicare billing

Part B allowed, 2024
$13,164
Medicare patients
41
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate21$46,168
VraylarCariprazine Hcl28$38,486
Aripiprazole32$4,615
Ziprasidone Hcl25$3,239
Methylphenidate ErMethylphenidate Hcl31$2,816
Buspirone Hcl91$1,707
Bupropion XlBupropion Hcl66$1,272
Fluvoxamine Maleate22$1,260
Venlafaxine Hcl ErVenlafaxine Hcl39$876
Duloxetine Hcl59$788
Fluoxetine Hcl83$633
Sertraline Hcl62$579
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine29$449
Olanzapine21$402
Trazodone Hcl66$402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$18$46,16821 claims
AbbVieVraylar$66$38,48628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 92 psychiatric/mental health providers in North Dakota.

Other psychiatric/mental health in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →